ImmunoGen forges co-operation agreement with CytomXs

|By:, SA News Editor

ImmunoGen (IMGN) forms a partnership with CytomXs Therapeutics to develop Probody-drug conjugate therapies for the treatment of cancer.

The co-operation brings together ImmunoGen's ADC technology for targeting cancer cells with CytomXs's Probody antibodies, which are designed to remain inert in healthy tissue but be activated in diseased cells. (PR)